Author: Janine Anthes

Diagnostic and surveillance limitations and lack of treatment options, vaccines hamper efforts

Guideline presents 19 sets of recommendations on diagnosis, prognosis, management/treatment

No benefit in healthy elderly patients; protective effect limited to those with type 2 DM aged 75 to 84

Moderate and strenuous activity in adolescence, young adulthood also not related to menopause risk

Larger tx effects for published versus unpublished trials; larger effects in non-English publications

Findings based on interviews with hospitals participating in Medicare bundled payments

Issues raised at AMA discussion include knowledge gaps for transgender women, screening guidelines

Grant is being given to Harm Reduction Therapeutics to develop low-cost, OTC naloxone nasal spray

The company, Civica Rx, will start with 14 widely used hospital drugs

No scientific proof for health claims made for three products sold online

Similar long-term survival, costs for endovascular and surgical revascularization procedures

Increase accompanied by a 47 percent decrease in the number of eligible but uninsured children

Review provides evidence-based strategies for identifying, managing, transitioning care

Expression of KLRD1 by natural killer cells before infection associated with influenza severity

Proportion of teens up to date with HPV vaccines also increasing; reached 48.6 percent in 2017

Reported death counts limited by physician lack of awareness of death certification process

Overall response of platelet count ≥50,000/μL seen in 43 percent of patients

Also, recommendations for type of insulin for type 1 and type 2 diabetes in low-resource settings